MAPS donated $26,616 to McLean Hospital, Harvard University, for Dr. John Halpern’s MAPS-sponsored study of the use of MDMA-assisted psychotherapy in subjects with anxiety associated with advanced-stage …
The FDA approved John Halpern’s MDMA/cancer anxiety study today.
A fateful step has been taken. Today, MAPS submitted Dr. John Halpern’s MDMA/cancer anxiety protocol and associated documents to the FDA. FDA should receive the protocol Monday, November 22 and will …
Harvard Medical School’s McLean Hospital Institutional Review Board (IRB) met to review the MAPS-sponsored pilot study designed to explore the use of MDMA-assisted psychotherapy in subjects with …
Dr. John Halpern submitted a lengthy response to the questions that we were asked to address by the IRB reviewing the MDMA/cancer anxiety study. Now we wait until the IRB meeting at the end of August to …
Dr. John Halpern has integrated preliminary comments from the McLean IRB and submitted revised versions of a protocol, informed consent, treatment manual, and the most recent update of the MDMA literature …
MAPS’ effort to start research at Harvard into the use of MDMA-assisted psychotherapy in subjects with anxiety associated with advanced cancer began a new phase today, as Dr. John Halpern submitted …
Dr. John Halpern of Harvard Medical School’s McLean Hospital submitted a protocol for review to the McLean Institutional Review Board (IRB) for a MAPS-sponsored study of MDMA in the treatment of …
[This is not the current version of this protocol] Version 4.1 August 22, 1995 A DOSE/RESPONSE HUMAN PILOT STUDY – SAFETY AND EFFICACY OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) IN MODIFICATION OF PHYSICAL …
